mardi 23 avril 2019

Onco Actu du 23 avril 2019


2. ETIOLOGIE



Mice Inherit Cancer Susceptibility Via Epigenetic Changes in Sperm [The Scientist]











3.1 PRÉVENTION - TABAC



Parents using both e-cigarettes and traditional cigarettes may be more motivated to quit [Mass. General Hospital]











3.3 PRÉVENTION - VACCINS



Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome? [NCI]










3.6 PRÉVENTION - ACTIVITÉ PHYSIQUE



Why Does Exercise Guard Against Cancer? Inflammation May Play a Role [NY Times]










4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



The Doctors Believed That the Woman Had Leukemia. But Could That Explain Her Horrible Rash? [NY Times]










4.10 DÉP., DIAG. & PRONO. - POUMON



A Deep-Learning Model May Help Predict Lung Cancer Survival and Outcomes [AACR]











4.12 BIOPSIES LIQUIDES



Blood samples to help select the right early phase clinical trials for cancer patients [Cancer Research UK]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Molecular Profiling of Cancer Patients Uncovers Combination Treatments in I-PREDICT Study [Genome Web]











5.10 TRAITEMENTS - ESSAIS



WINTHER Trial Highlights Challenges, Potential of Transcriptomics for Precision Oncology [Genome Web]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Redesigned CAR-T eliminates dangerous cytokine release syndrome in lymphoma trial [Fierce Biotech]











With some tweaks, CAR-T cancer therapy could be made safer — and more widely available — study suggests [STAT]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Poseida to Advance CAR-T For Myeloma with Novartis-Led $142M Round [Xconomy]










CAR-T maker Poseida forgoes IPO, hauls in $142M series C instead [Fierce Biotech]











Poseida Therapeutics Raises $142 Million in Series C Financing [Poseida]











5.12.6 IMMUNOTHÉRAPIES - AMM



Merck heaps early pressure on Bristol-Myers' Opdivo with Keytruda's kidney cancer debut [Fierce Pharma]










FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) [Merck]











As rivals wait in line, Merck’s Keytruda scores early FDA nod for frontline patients with the most common form of kidney cancer [EndPoints]











FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma [FDA]











Merck's Keytruda wins FDA approval as combination therapy for kidney cancer [Reuters]











5.2.3 PHARMA - ÉCONOMIE



Big Pharma Cuts, Current and Coming [In The Pipeline]











How biopharma companies use NIH and vice versa [EndPoints]











5.9 AACR



AACR Annual Meeting 2019: Patients as Partners in the Research Process [Cancer Research Catalyst]










6.12 ETHIQUE



Safeguards for human studies can’t cope with big data [Nature]










6.6 PUBLICATIONS



Harvard cancer lab subject to federal misconduct probe [Retraction Watch]











6.7.1 IA/BIOINFORMATIQUE



New Bioinformatics Portal Provides One-Stop Shop for Multi-Omics Data Analysis [Genome Web]











Crowdsourced AI learns to target lung tumors for radiation [Reuters]











6.8 COMMUNICATION



Case Reports in the Age of Twitter [The American Journal of Medicine]











6.9 CONTROVERSES



Wary of Chinese Espionage, Houston Cancer Center Chose to Fire 3 Scientists [NY Times]











Three Researchers Ousted from MD Anderson [The Scientist]











MD Anderson addresses national threat of foreign influence [MD Anderson Cancer Center]











Exclusive: Major U.S. cancer center ousts ‘Asian’ researchers after NIH flags their foreign ties [Science]